S-1/A: BriaCell Therapeutics Files S-1/A for Up to $20 Million Offering Amid Promising Cancer Immunotherapy Clinical Data

BriaCell Therapeutics Corp. filed an S-1/A registration statement to offer up to 6,825,938 common units and pre-funded units, aiming to raise approximately $18.04 million to advance its clinical-stage cancer immunotherapies, Bria-IMT and Bria-OTS, which have shown promising survival and response rates in metastatic breast cancer.

Summary

• BriaCell Therapeutics Corp. is offering on a best efforts basis up to 6,825,938 common units, each consisting of one common share and one BCTXZ Warrant, at an assumed public offering price of $2.93 per Common Unit.
• The company is also offering pre-funded units, each consisting of one pre-funded warrant and one BCTXZ Warrant, for purchasers whose ownership would exceed 4.99% (or 9.99% at election) of outstanding common shares.
• The estimated net proceeds from the offering, assuming all securities are sold and no Pre-Funded Units are issued, are approximately $18.04 million, intended for working capital, general corporate purposes, and advancement of business objectives.
• BriaCell is advancing its Bria-IMT targeted immunotherapy in a pivotal Phase 3 study for metastatic breast cancer, which has Fast Track Designation by the U.S. FDA.
• Clinical data for Bria-IMT showed a 71% (5/7) intracranial objective response rate (iORR) in patients with central nervous system (CNS) metastases.
• Median progression-free survival (PFS) for Bria-IMT in heavily pre-treated metastatic breast cancer patients was 3.5 months, with the Phase 3 formulation showing 4.2 months, approximately twice the PFS reported for treatment of physicians choice (TPC) in similar studies.
• Median overall survival (OS) for Phase 2 patients treated with the Phase 3 formulation of Bria-IMT was 15.6 months (17.3 months for those treated since 2022), which is superior to outcomes reported for comparable patients in the literature (5.9-9.8 months).
• A one-year survival rate of 55% was reported for patients in the Phase 2 study treated with the Phase 3 formulation of Bria-IMT, compared to 30-40% for current standard of care.
• BriaCell is also conducting a Phase 1/2 study (NCT06471673) for Bria-OTS, a personalized next-generation immunotherapy, which has shown sustained complete resolution of lung metastasis in one patient.
• The Data Safety Monitoring Board (DSMB) completed its first safety review of the pivotal Phase 3 study for Bria-IMT and recommended its continuation with no safety concerns.
• The company's majority-owned subsidiary, BriaPro Therapeutics Corp., is developing novel, high-affinity antibodies to B7-H3 and plans to incorporate them into its Bria-TILsRx platform.
• As of April 30, 2025, the company reported a net loss of $(18,392,033) for the nine months ended April 30, 2025, compared to $(3,682,796) for the same period in 2024.
• The company completed a 1-for-15 common share consolidation effective January 24, 2025, to comply with Nasdaq listing requirements.

Sentiment

Score: 8

Explanation: The document highlights highly promising clinical trial results for Bria-IMT and Bria-OTS in metastatic breast cancer, including superior survival rates compared to standard of care and significant responses in difficult-to-treat patient populations like those with CNS metastases. The FDA Fast Track designation and positive DSMB review further bolster confidence in the lead program. However, the company continues to incur substantial operating losses, and the current offering will result in immediate and significant dilution for investors, which are notable financial negatives.

Positives

• Bria-IMT has received FDA Fast Track Designation, which is intended to accelerate the review process for novel treatments addressing unmet medical needs.
• Clinical data for Bria-IMT shows a high 71% (5/7) intracranial objective response rate (iORR) in advanced breast cancer patients with CNS metastases, a dire clinical situation with very few effective therapies.
• Bria-IMT demonstrated a median progression-free survival (PFS) of 4.2 months with the Phase 3 formulation, approximately twice the PFS figures reported for treatment of physicians choice (TPC) in similar studies (1.6-2.3 months).
• Median overall survival (OS) for Bria-IMT Phase 2 patients treated with the Phase 3 formulation (17.3 months for those treated since 2022) is superior to outcomes reported for comparable patients in the literature (5.9-9.8 months).
• The one-year survival rate of 55% for Bria-IMT Phase 2 patients (Phase 3 formulation) exceeds the 30-40% survival expectations with current standard of care therapies.
• Bria-IMT shows clinical benefit across multiple breast cancer subtypes, including 100% CBR in HER2+, 63% CBR in HR+/HER2-, and 66% CBR in HR-/HER2 low subtypes in ADC-resistant patients.
• Bria-IMT has a favorable safety profile with no reported incidents of interstitial lung disease (ILD) or treatment-related discontinuations, which are common serious adverse events with ADCs.
• Bria-OTS, the personalized off-the-shelf immunotherapy, demonstrated sustained complete resolution of lung metastasis in a hormone receptor-positive (HR+), HER2-negative, metastatic breast cancer patient.
• The Data Safety Monitoring Board (DSMB) found no safety concerns and recommended the continuation of BriaCell's pivotal Phase 3 study for Bria-IMT.
• FDA authorized an Expanded Access Policy (EAP) for Bria-IMT, providing access to metastatic breast cancer patients in need beyond the scope of the clinical trial.
• Positive feedback from the FDA Pre-IND meeting for Bria-PROS+ in prostate cancer, clarifying the development pathway by not requiring animal toxicology and pharmacokinetic studies for IND opening.
• BriaPro Therapeutics Corp., a majority-owned subsidiary, is developing novel, high-affinity antibodies to B7-H3, a promising cancer drug target, and has filed provisional US patent applications.

Negatives

• The company reported a significant net loss of $(18,392,033) for the nine months ended April 30, 2025, indicating ongoing unprofitability.
• Investors in this offering will experience immediate and substantial dilution in the book value of their investment, estimated at $0.74 per share.
• The offering is on a 'best efforts' basis with no minimum offering amount, meaning the company may sell fewer than all securities and receive substantially less proceeds than the maximum target.
• There is no established public trading market for the Pre-Funded Warrants, and no market is expected to develop, limiting their liquidity.
• The public trading market for the BCTXZ Warrants is currently not very active, which may affect their market price and liquidity.
• The BCTXZ Warrants are speculative in nature and may expire without value if the common share market price does not equal or exceed the exercise price of $5.25.
• The company has a history of not meeting Nasdaq listing requirements, including minimum market value of listed securities and minimum bid price, although compliance was regained.

Risks

• Inability to maintain listing of securities on Nasdaq or TSX could adversely affect share price, liquidity, and ability to obtain financing.
• Investors in this offering will experience immediate and substantial dilution in the book value of their investment.
• Management will have broad discretion over the use of proceeds from this offering, and the application of these proceeds might not increase the value of an investment.
• Future capital raises through the issuance of equity or debt securities could dilute existing ownership and negatively impact the trading price of common shares.
• The public trading market for the BCTXZ Warrants is not very active, and there is no public market for the Pre-Funded Warrants, limiting liquidity.
• The BCTXZ Warrants are speculative and may expire without value if the market price of common shares does not exceed the exercise price.
• A possible short squeeze due to sudden demand exceeding supply may lead to price volatility in common shares.
• The current offering may cause an immediate decrease in the trading price of common shares due to the increased number of shares and warrants available.
• Inability to adequately protect intellectual property rights could affect the company's ability to compete.
• Changes in federal, state, and foreign laws and regulations, or their administrative interpretations, could increase compliance costs or impact the ability to obtain or maintain regulatory approval for products.

Future Outlook

The company anticipates completing patient enrollment in its pivotal Phase 3 study for Bria-IMT in late 2025 or early 2026 and may report top-line data as early as H1-2026. Positive results from this study could lead to full FDA approval and marketing authorization for Bria-IMT in metastatic breast cancer. BriaCell also expects to use its enhanced Bria-OTS+ platform (specifically Bria-BRES+ and Bria-PROS+) in upcoming Phase 1/2a clinical studies for breast and prostate cancer, respectively.

Management Comments

• "BriaCell will continue to monitor the data in this subgroup of patients including a pre-planned subgroup analysis in the current pivotal Phase 3 study in metastatic breast cancer. Treatment of patients with CNS metastatic disease represents a potential additional indication for market approval of Bria-IMT."
• "BriaCell believes Bria-OTS+ may deliver significant clinical efficacy and survival benefits in breast cancer and prostate cancer, respectively."
• "BriaCell is excited to collaborate on this important program with authors and BriaCell medical advisory board members Sara A. Hurvitz, MD, Professor of Medicine, Fred Hutchinson Cancer Center, Adam M. Brufsky, MD, PhD, Professor of Medicine, University of Pittsburgh School of Medicine, and Massimo Cristofanilli, MD, Professor of Medicine, Weill Cornell Medical College, Cornell University."
• "BriaCell is closely monitoring ADC resistant patients in its ongoing pivotal Phase 3 study of Bria-IMT and CPI in metastatic breast cancer."
• "Final Phase 2 OS calculation was pending as many patients remain alive well over 1 year after starting the study."
• "BriaCell anticipates completing patient enrollment in late 2025 or early 2026, and may report top line data as early as H1-2026."

Industry Context

BriaCell Therapeutics operates in the highly competitive and rapidly evolving field of cancer immunotherapy, a forefront area in cancer treatment that harnesses the body's own immune system. The company's focus on metastatic breast cancer and prostate cancer addresses significant unmet medical needs, particularly for heavily pre-treated and resistant patient populations. By developing novel immunotherapies like Bria-IMT and personalized off-the-shelf treatments like Bria-OTS, BriaCell aims to offer alternatives or improvements over existing standard of care therapies, including antibody-drug conjugates (ADCs) and chemotherapy, which are often associated with significant side effects or limited efficacy in advanced stages.

Comparison to Industry Standards

• Bria-IMT regimen's median progression-free survival (PFS) of 3.5 months in heavily pre-treated patients is comparable to or approximately twice the PFS figures reported for treatment of physicians choice (TPC) in other similar studies, such as Cortes J et al. (2011) at 1.7 months, Bardia A et al. (2024) at 1.7 months, Tripathy D et al. (2022) at 1.9 months, and O'Shaughnessy J et al. (2022) at 1.6-2.3 months.
• The median overall survival (OS) of 15.6 months for Bria-IMT patients (Phase 3 formulation since 2022) significantly exceeds the 5.9-9.8 months reported for similar patients in the literature, including Cortes et al. (2018) at 9.1-9.3 months and Kazmi et al. (2020) at 7.2-9.8 months.
• Bria-IMT's one-year survival rate of 55% for Phase 2 patients (Phase 3 formulation) surpasses the 30-40% survival expectations with current standard of care therapies, such as Cortes et al. (2018) at ~38-40% and Kazmi et al. (2020) at 30-38%.
• In hormone receptor-positive (HR+) metastatic breast cancer, Bria-IMT plus CPI achieved a median OS of 17.3 months, outperforming the FDA-approved ADC TRODELVY (sacituzumab govitecan-hziy) at 14.4 months and single agent chemotherapy at 11.3 months.
• For triple-negative breast cancer (TNBC), Bria-IMT plus CPI showed a median OS of 11.4 months, which is comparable to TRODELVY (11.8 months) in the pivotal Phase 3 ASCENT study, but almost twice the OS of the TPC arm (6.9 months) in the same study.
• In HR+/HER2metastatic breast cancer, Bria-IMT (Phase 3 formulation) demonstrated a median OS of 17.3 months, which is higher than both the sacituzumab govitecan (14.4 months) and chemotherapy (11.2 months) arms in the pivotal Phase 3 TROPiCS-02 study (Rugo HS et al., 2023).
• The 71% intracranial objective response rate (iORR) observed with the Bria-IMT regimen in patients with CNS metastases is particularly notable, as the document states that very few therapies have shown any effect on CNS or intracranial metastases in breast cancer, highlighting a significant unmet medical need.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Face potential significant dilution from the current offering and future capital raises. May benefit from increased share price if clinical trials are successful and products gain regulatory approval. Risk of delisting if Nasdaq requirements are not consistently met.
• Patients: Stand to benefit from potential novel, effective immunotherapies for metastatic breast cancer and prostate cancer, especially those who are heavily pre-treated or resistant to existing therapies, offering improved survival and quality of life. The FDA's Expanded Access Policy provides Bria-IMT to patients in need beyond clinical trials.
• Employees: Continued employment and potential growth opportunities are dependent on the successful progression of the company's clinical pipeline and financial stability.
• Creditors/Suppliers: The company's ability to meet its financial obligations and continue operations is contingent on successful capital raises and the advancement of its clinical development programs.

Next Steps

• Complete patient enrollment in the pivotal Phase 3 study for Bria-IMT in late 2025 or early 2026.
• Report top-line data from the pivotal Phase 3 study as early as H1-2026.
• Continue monitoring data in the CNS metastatic disease subgroup for Bria-IMT in the pivotal Phase 3 study.
• Continue monitoring ADC resistant patients in the ongoing pivotal Phase 3 study of Bria-IMT and CPI.
• Initiate Phase 1/2a clinical studies for Bria-OTS+ (Bria-BRES+ and Bria-PROS+).
• Continue GMP manufacturing for Bria-PROS+ to generate clinical supplies.
• Develop novel, high-affinity antibodies to B7-H3 and incorporate them into the Bria-TILsRx platform.
• File an international patent application under the Patent Cooperation Treaty (PCT) for the B7-H3 antibody technology.
• Potentially pursue full FDA approval and marketing authorization for Bria-IMT in MBC patients based on positive Phase 3 results.
• Continue dosing patients in Bria-OTS combination with checkpoint inhibitor in metastatic breast cancer.

Key Dates

Recommendation

Keywords

BriaCell Therapeutics, BCTX, BCT, Bria-IMT, Bria-OTS, Bria-PROS+, immunotherapy, metastatic breast cancer, prostate cancer, cancer treatment, clinical trial, Phase 3, Phase 1/2, FDA Fast Track, oncology, biotechnology, SEC filing, S-1/A, public offering, warrants, dilution, clinical data, overall survival, progression-free survival, CNS metastases, ADC resistant